In patients with prostate cancer, there are changes in antioxidant defense capacity, such as increased plasma concentrations of thiobarbituric acid-reactive substances (TBARS), increased serum protein carbonylation, decreased whole blood catalase (CAT) activity, increased superoxide dismutase (SOD) activity, and increased plasma and red blood cell thiol levels. Here, CAT is linked to prostate carcinoma.